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Abstract
 
Type 1 diabetes and other organ-specific autoimmune diseases often cluster together in human
families and in congenic strains of NOD (nonobese diabetic) mice, but the inherited immuno-
regulatory defects responsible for these diseases are unknown. Here we track the fate of high
avidity CD4 T cells recognizing a self-antigen expressed in pancreatic islet 
 
 
 
 cells using a trans-
genic mouse model. T cells of identical specificity, recognizing a dominant peptide from the
same islet antigen and major histocompatibility complex (MHC)-presenting molecule, were
followed on autoimmune susceptible and resistant genetic backgrounds. We show that non-
MHC genes from the NOD strain cause a failure to delete these high avidity autoreactive T
cells during their development in the thymus, with subsequent spontaneous breakdown of
CD4 cell tolerance to the islet antigen, formation of intra-islet germinal centers, and high titre
immunoglobulin G1 autoantibody production. In mixed bone marrow chimeric animals, de-
fective thymic deletion was intrinsic to T cells carrying diabetes susceptibility genes. These re-
sults demonstrate a primary failure to censor forbidden clones of self-reactive T cells in inher-
ited susceptibility to organ-specific autoimmune disease, and highlight the importance of
thymic mechanisms of tolerance in organ-specific tolerance.
Key words: autoimmune disease • diabetes mellitus type I • clonal deletion • T lymphocytes • 
genetic predisposition to disease
 
Introduction
 
Autoimmune diseases that target specific organs such as the
pancreatic islets, thyroid, adrenal glands, stomach, or ner-
vous system, often cluster together in either different family
relatives or occur simultaneously in one individual. High
concordance among identical twins indicates a large inher-
ited component in susceptibility to these diseases, and ge-
netic studies reveal a complex pattern of interactions be-
tween MHC and non-MHC chromosomal regions (1).
The nature of the inherited immunological defect(s) that
leads to these diseases nevertheless remains obscure. On the
one hand, a variety of lines of evidence suggest that these
diseases may reflect excessive stimulation of autoreactive T
cells by viruses, costimulatory molecules, or antigen-pre-
senting cells that promote Th1 T cells (2–4). Alternatively
these diseases may be related to observed heritable de-
creases in Th2 cells (5), regulatory T cells (3, 6), NKT cells
(7, 8), CD4
 
 
 
CD25
 
 
 
 
 
regulatory T cells (9), or diminished
thymocyte signaling (10) or thymocyte apoptotic responses
measured in vitro (11). Defects in antigen presentation and
peripheral censoring of autoreactive T cells by processes
such as clonal anergy or activation-induced death have also
been proposed (12–16). One of the principal barriers to
identifying the primary inherited defects, however, has
been the inability to track the fate of organ-reactive T cells
directly in vivo and identify primary inherited aberrations
in this fate in autoimmune susceptible individuals.
Inherited susceptibility to autoimmune disease in the
NOD (nonobese diabetic)
 
*
 
 mouse strain represents a key
model to begin identifying the primary immunological le-
sions underlying the clustering of different organ-specific
autoimmune diseases (17). NOD mice spontaneously de-
velop type 1 diabetes due to autoreactive T cell destruction
of pancreatic islet 
 
 
 
 cells. A particular allelic product of the
NOD strain MHC, I-A
 
g7
 
, is a key diabetes susceptibility
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gene and shares unique sequence and structural motifs with
diabetes-susceptible MHC gene products in humans (18,
19). Like humans, diabetes in NOD mice nevertheless re-
quires many other susceptibility genes other than the
MHC, and elegant mapping and congenic breeding strate-
gies have delineated the complex nature of inherited sus-
ceptibility (1, 20, 21).
C57BL/6 or C57BL/10 strain mice, which are not espe-
cially prone to organ-specific autoimmunity, do not de-
velop insulitis or diabetes when the NOD MHC haplotype
is introduced by congenic breeding, underscoring the im-
portance of other non-MHC genes. In fact, substituting a
number of different non-MHC chromosomal regions from
the C57BL/10 strain into the NOD strain by congenic
breeding, either individually or in combination, is sufficient
to partially or completely prevent development of insulitis
or diabetes despite the continued presence of the NOD
MHC alleles (1, 21, 22). Conversely, when a different
MHC type is introduced into the NOD strain, as in the
NOD.H-2
 
k
 
 congenic derivative, insulitis and diabetes are
prevented but autoimmune thyroiditis is exaggerated (21,
23, 24). Introducing a defective B7.2 (CD86) costimula-
tory gene into NOD suppresses insulitis and diabetes but
leads instead to spontaneous autoimmune damage of the
peripheral nerves (25). These results point to a general sus-
ceptibility to organ-specific autoimmunity in NOD caused
by a complex set of non-MHC genes, with alleles of MHC
or costimulatory molecules influencing the specific organ
targets of this general immunological defect (1, 21).
In addition to the complicated inheritance of autoim-
mune susceptibility, the complexity and heterogeneity of
the normal T cell repertoire also represents a barrier to vi-
sualizing the primary immunological defects underlying
autoimmune susceptibility. Self-reactive T cells can be
readily demonstrated in the circulation and peripheral tis-
sues of animals and individuals with no apparent predispo-
sition to autoimmune disease, but the heterogeneity in
TCR specificity and affinity and the need to use functional
response assays to measure these cells makes it difficult to
interpret the presence of these cells. Censoring of self-reac-
tive T cells through the induction of clonal deletion or
clonal anergy in the thymus and in peripheral lymphoid
tissues requires a critical threshold of antigen/MHC and
TCR affinity to be triggered. For organ-specific antigens
that are present in only trace amounts in the thymus or cir-
culation, many T cells fall below this threshold and escape
thymic deletion (26–32) because either the T cells have
lower affinity or TCR density, the peptide/MHC combi-
nations they recognize are less efficiently presented, or they
recognize unique epitopes that are only generated in the
peripheral organ.
Three different TCR transgenic models that employ
TCRs from islet reactive clones that could be grown in
vitro from autoimmune mice represent examples of clones
that fall below this thymic selection threshold, although the
islet antigens recognized by these TCRs are not yet known
(33, 34). Peripheral deletion or other regulatory mecha-
nisms may normally prevent T cells of this type from be-
 
coming activated (15, 35). Nevertheless, many organ-spe-
cific antigens do reach the circulation and thymus in low
amounts (eg. insulin, thyroglobulin), and a great number
appear to be made there by rare thymic medullary epithe-
lial cells (36, 37). Efficiently presented dominant peptides
from these self-antigens can be shown to censor reactive T
cells by thymic deletion and by causing selective export of
anergic CD4
 
 
 
CD25
 
 
 
 cells that may be responsible for reg-
ulating the clones that fall below these thymic selection
screens (32, 38–46). The relative roles of thymic and pe-
ripheral mechanisms for achieving organ-specific tolerance
and the pathogenesis of autoimmune disease thus remains a
key unresolved issue.
To study how the (non-MHC) general autoimmune
susceptibility genes in NOD mice affect the acquisition of
tolerance by organ-specific CD4 T cells, we sought to
compare the fate of islet-reactive CD4 T cells bearing a
well-defined high avidity TCR in a TCR transgenic
mouse model, when bred to H-2 matched strains with
an underlying autoimmune susceptible or resistant back-
ground. By holding the TCR, the islet antigen and the
H-2–presenting molecules constant, and varying the non-
MHC background genes, we show here that non-MHC
genes from the NOD strain act within high avidity autore-
active CD4 T cells to cause them to escape clonal deletion
in the thymus and reach the peripheral lymphoid organs
and pancreatic islets in greatly elevated numbers.
 
Materials and Methods
 
Mice, Antibodies, Histology.
 
3A9 TCR transgenic (47) and
ILK-3 Ins-HEL transgenic mice (32) produced in C57BL/6J
were backcrossed to B10.Br/SgSnJ (JAX) or NOD.H2
 
k
 
 (48) (gift
from L. Wicker, Cambridge University, Cambridge, UK). Data
presented are from N5-N10 mice. TCR, transgenic mice ex-
pressing HEL under the rat insulin promoter (insHEL), and H-2
genotype of each mouse was tested twice by PCR (32). Urine
glucose was tested using Testape at biweekly intervals or when
cage was wet. Mice with two successive positive Testape were
called diabetic, euthanized, and diabetes confirmed by blood glu-
cose measurement. Nondiabetic mice were culled at 6 mo. From
each mouse, one-half pancreas was fixed in 10% formalin, paraf-
fin embedded, and stained with H&E, while the other half was
snapped frozen in OTC (Tissue Tek) in liquid nitrogen. Frozen
sections were stained with peanut agglutinin biotin/streptavidin-
alkaline phosphatase/Fast Blue (all from Vector Labs) and with
sheep anti–mouse IgD/anti–sheep HRP (both from The Binding
Site)/DAB. HEL-binding IgG was measured in serum by ELISA
on Nunc maxisorp plates coated with 100
 
  
 
g/ml HEL, devel-
oped with sheep anti–mouse IgG-alkaline phosphatase (Southern
Biotech Associates, Inc.) and Sigma Substrate 104. A reference
pool of immune sera from HEL primed and boosted B6 mice was
set to contain 100 arbitrary units. Radiation chimeras were con-
structed as described previously (32), using a total of 2 
 
 
 
 10
 
6
 
bone marrow cells to reconstitute recipients irradiated with
5.5Gy twice separated by 3 h. Recipients were analyzed 6–10 wk
after reconstitution, therefore diabetes was not monitored in
these mice.
 
Flow Cytometry.
 
6–12-wk old nondiabetic mice (Testape
negative) were analyzed. Thymus and spleen were passed 
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through a sterile cell strainer. Lymphocytes from pancreatic
lymph nodes were obtained by pressing between two glass slides.
Liberase R1 (Boehringer) was injected into the common bile
duct of double transgenic mice to inflate the pancreas. The pan-
creas was then incubated 20 min at 37
 
 
 
C, and washed with a so-
lution containing FCS. Islets were handpicked and dissociated
using a protein gel-loading pipette tip. The following antibody
stains were used: mouse IgG1 anti-clonotypic 1G12 antibody
(49) (gift of E. Unanue and D. Peterson, Washington University,
St. Louis, MO) as culture supernatant followed by rat monoclo-
nal anti–mouse IgG1 conjugated to FITC or allo-phycocyanin
(BD PharMingen); anti–CD8-PE (Caltag); anti-CD4 allo-phyco-
cyanin, anti-CD3, anti-CD69, anti-Va2, anti-CD45.1-biotin,
and anti-CD45.2-biotin (all from BD PharMingen), anti-CD24
biotin (Caltag), anti-Vb8 biotin (clone F23.1), and streptavidin-
PerCP (BD). Data was collected on a Becton Dickinson LSR,
and analyzed with WinList™, CELLQuest™ PRO, and
FlowJo™.
 
Results
 
To track how the acquisition of CD4 T cell tolerance to
organ-specific self-antigens is altered by the general au-
toimmune susceptibility genes from NOD, we used an ex-
perimental model involving a cross between two transgenic
mouse strains. In the 3A9 TCR transgenic strain (47) many
CD4 T cells carry the same TCR recognizing a normally
foreign antigen, hen egg lysozyme (HEL) peptide 46–61
bound to I-A
 
k
 
 (50). HEL 46–61 is the dominant peptide
epitope presented by I-A
 
k
 
, and its high avidity binding to
I-A
 
k
 
 and recognition by the 3A9 TCR (Vb8.2/Va3) are
very well characterized (50). T cells bearing the 3A9 TCR
can be readily detected in vivo with a clonotypic anti-
TCR mAb developed by Peterson and Unanue (reference
49, Fig. 2). The insHEL transgenic strain synthesizes high
concentrations of membrane-bound HEL as a self-antigen
in pancreatic islet 
 
 
 
 cells under control of the rat insulin
promoter (32). Trace quantities of cleaved HEL are present
in the circulation, mirroring the distribution of insulin itself
(32). When the two transgenic strains are intercrossed to
make TCR/insHEL double-transgenic progeny, the large
population of HEL-reactive T cells now reacts with the is-
let-specific self-antigen, and the fate of these T cells can be
readily studied.
Previously we showed that TCR/insHEL double trans-
genic mice on the (B6
 
 
 
B10.BR)F1 background remain
free of diabetes, but develop early and extensive insulitis that
remains subclinical or “benign” (32). The insulitis was ex-
plained by thymic export of large numbers of CD4 T cells
that had reduced but not lost their responsiveness to HEL so
that high concentrations of HEL such as exist in the islet
could elicit a weak response by most of the cells (32). The
weakened responsiveness of the T cells reflected two
changes: (i) selective downregulation of the transgene-encode
TCR Va3/Vb8.2 pairs, while still retaining a sufficient den-
sity of TCRs to allow survival by coexpressing a second
TCR-
 
 
 
 chain; and (ii) an independent diminished respon-
siveness of the T cells to TCR stimulation revealed by stim-
ulating all the surface TCRs with anti-Vb8.2 antibody (32).
 
Spontaneous Progression of Insulitis to Form Germinal Centers
and Autoantibody.
 
We backcrossed the TCR and insHEL
transgenic strains to two H-2
 
k
 
 matched congenic partner
strains: NOD.H-2
 
k
 
 (reference 48; referred to below as
NOD
 
k
 
) which carries all the autoimmune susceptibility al-
leles of NOD except the H-2, and hence normally lacks in-
sulitis or diabetes but is susceptible to autoimmune thy-
roiditis and sialitis; and B10.BR (referred to below as
B10
 
k
 
), which carries diabetes resistance alleles at most non-
MHC diabetes loci (51). Then, we intercrossed mice carry-
ing TCR and insHEL transgenes to produce TCR/insHEL
double transgenic mice of three genetic makeups: NOD
 
k
 
,
B10
 
k
 
, and (NOD
 
k
 
 
 
  
 
B10
 
k
 
)F1.
The effects of the different strain backgrounds were first
determined by studying large cohorts of female TCR/
insHEL animals and littermate controls until 24 wk old. No
autoimmune diabetes or insulitis developed in NOD
 
k
 
,
B10
 
k
 
, or F1 hybrid progeny carrying either the TCR or
insHEL transgenes alone, or neither transgene. The lack of
insulitis or diabetes in the NOD
 
k
 
 animals reflects the inhib-
itory effects of this H-2 haplotype on islet-specific autoim-
munity in NOD mice (but not on thyroid or salivary au-
toimmunity; references 21 and 51). By contrast all TCR/
insHEL double transgenic mice had extensive lymphocytic
infiltrates in pancreatic islets by 6 wk old regardless of the
strain background, and this inflammation persisted to the
24-wk time point (Fig. 1 A). As discussed above, the spon-
taneous insulitis in double-transgenic mice on the autoim-
mune resistant strain backgrounds (B10
 
k
 
 and F1) can be ex-
plained by the presence of HEL-reactive TCRs on most of
the peripheral CD4s, albeit expressed at reduced cell sur-
face density and weak responsiveness to antigen. It is im-
portant to note, however, that the populations of T cells
and IgD
 
 
 
 resting B lymphocytes in these chronically in-
flamed islets reflects the lymphocyte populations in the cir-
culation (Fig. 1, and data not shown), and the majority
probably accumulate in these sites secondary to chronic in-
flammation and independently from activation or any spec-
ificity for the inciting HEL antigen. The presence of infil-
trating cells therefore give little information about the
frequency or responsiveness of the minority of HEL-spe-
cific Th cells among them.
In contrast to the absence of autoimmune diabetes in
insHEL or TCR animals on the NOD
 
k
 
 background, 90%
of TCR/insHEL double transgenic mice developed diabetes
on this background. Diabetes onset occurred over a broad
age range from 8–24 wk old (Fig. 1 B) and was accompa-
nied by formation of large germinal centers in the pancre-
atic islets (Fig. 1 A) and spontaneous secretion of high titre
anti-HEL IgG1 autoantibodies in the serum (Fig. 1 C).
Only 20% of B10
 
k
 
 TCR/insHEL animals developed diabe-
tes, and this appeared to reflect a distinct disorder because it
developed only during a narrow age window in mice 
 
 
 
12
wk old, and none of these animals produced measurable
anti-HEL IgG autoantibody in their serum (Fig. 1 C) or
had discernible germinal centers in the islets. Consistent
with a different genetic basis, the B10
 
k 
 
form of low-inci-
dence/antibody-free diabetes was completely suppressed by 
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one full set of non-MHC genes from NOD in F1-hybrids,
and likewise the NOD
 
k
 
 form of high incidence/high au-
toantibody disease was fully suppressed by non-MHC B10
genes (Fig. 1 B).
 
Defective Censoring of Islet Reactive CD4 Cells in NOD
 
k
 
.
 
The progression to diabetes, formation of germinal centers,
and secretion of anti-HEL IgG in NOD
 
k
 
 double transgenic
mice indicated that the 3A9 HEL-reactive CD4 T cells ei-
ther failed to be tolerized or broke out of tolerance as a re-
sult of non-MHC NOD genes. To explore this issue, CD4
T cells bearing the 3A9 anti-HEL TCR were measured in
different tissues of young mice before the onset of diabetes
by flow cytometric staining with the 1G12 anti-clonotypic
antibody (Fig. 2). In TCR-transgenic mice lacking insHEL
antigen, a high frequency of CD4
 
 
 
 TCR clonotype
 
 
 
 cells
was present in the spleen and lymph nodes regardless of the
strain background. By contrast, while the frequency of pe-
ripheral CD4
 
 
 
 TCR clonotype
 
 
 
 cells was reduced in all
TCR/insHEL double-transgenic mice, much higher num-
bers of islet reactive T cells were present in the spleen, pan-
creatic lymph nodes, and pancreatic islets in the NOD
 
k
 
 an-
imals. The failure to eliminate islet reactive T cells in NOD
appears to be a recessive defect as it was fully corrected in
(NOD
 
k
 
 
 
  
 
B10
 
k
 
)F1 hybrid animals.
Receptor downregulation is an important means of di-
minishing antigen reactivity, and almost all CD4
 
 
 
 T cells
in the periphery of TCR/insHEL B10
 
k
 
 mice display half
the surface density of CD3 and V
 
 
 
8 that are found on
TCR transgenic mice without the negative-selecting anti-
gen (Fig. 3 A and Fig. 4). Most of these T cells carry the
transgenic V
 
 
 
3 chain on their surface, but at 10-fold re-
duced levels compared with TCR cells (Fig. 3 B) so that
they are difficult to detect by staining with the clonotypic
1G12 antibody (Fig. 3 A). Since transgenic V
 
 
 
8 chains on
these cells are only reduced by 50%, the remaining recep-
tors must contain a second TCR-
 
 
 
 chain. This conclusion
is supported by the fact that V
 
 
 
2 chains are expressed by a
fraction of these cells, and by the finding that the level of
V
 
 
 
2 displayed on their surface is about half that found on
nontransgenic mice (Fig. 3 C). By contrast, very little de-
crease in CD3 or V
 
 
 
8 occurred on peripheral CD4 T cells
from NOD
 
k
 
 TCR/insHEL mice, and a large fraction still
express high surface densities of clonotypic receptor 1G12
(Fig. 3 A). Thus, insHEL caused a dramatic reduction in
Figure 1. Islet-reactive T cells cause germinal center formation, autoantibodies, and diabetes in NODk mice. (a) Pancreatic islets stained with H&E
from TCR/InsHEL mice of the indicated genotypes. Right panel is a frozen section stained with peanut agglutinin (blue) and anti-IgD (brown). GC,
germinal center. (b) Onset of diabetes in TCR/insHEL female mice of the indicated genotypes. Data represent  20 mice per group. (c) HEL-binding
IgG titre in serum from diabetic double transgenic mice, collected within 2 wk of diabetes onset. Titres are expressed in arbitrary units relative to a refer-
ence immune sera from HEL-immunized nontransgenic mice set at 100 units. 
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the avidity of peripheral T cells reacting with HEL on the
B10
 
k
 
 background, but induced little change compared
with TCR-transgenic animals without HEL on the
NOD
 
k
 
 background.
A similar difference in HEL-reactive TCR expression was
exhibited by the lymphocytes that infiltrated pancreatic islets
of NOD
 
k
 
 and B10
 
k
 
 mice. Like the circulating T cells, infil-
trating CD4
 
 
 
 T cells show less reduction in CD3 or Vb3 in
 
NOD
 
k
 
 TCR/insHEL animals compared with the B10
 
k
 
counterparts (Fig. 4). Consistent with a difference in respon-
siveness to HEL made in the pancreatic islets, clonotype-
positive CD4 cells specifically increased expression of CD69
in the islets relative to their levels in lymph nodes or spleen
(Fig. 5). Clonotype-negative cells in the same islet infiltrates
showed no induction of CD69 (Fig. 5). Likewise, no specific
increase in CD69 occurred on clonotype-positive CD4 cells
in the islets of B10k double transgenic mice (Fig. 5). While
these data indicate a difference in the number of high avidity
autoreactive T cells homing to the islet, the majority of islet
infiltrating cells are nevertheless likely to have been attracted
independently of their antigen specificity, since the infiltrate
is broadly composed of B cells, clonotype-positive and -neg-
ative CD4 and CD8 cells (Fig. 1, and data not shown).
 
Defective Thymic Deletion of Islet Autoreactive T Cells.
 
The presence of large numbers of high avidity T cells in
NOD
 
k
 
 insHEL/TCR animals could reflect expansion of
these cells as a result of dysregulated peripheral tolerance
mechanisms, or failure to delete these cells in the thymus.
Analysis of thymocytes from the double-transgenic mice
showed a failure to eliminate high avidity islet reactive T
cells during their development in the thymus (Fig. 6).
In TCR-transgenic mice lacking insHEL, strong positive
selection is evidenced by the skewing to form a large popu-
lation of CD4
 
 
 
8
 
  
 
single-positive thymocytes (Fig. 6 A). In
both NOD
 
k
 
 or B10
 
k
 
 backgrounds most of these single-pos-
itive thymocytes bear high surface densities of the 3A9
TCR based on 1G12 staining (Fig. 6 B). In double-trans-
genic B10
 
k
 
 mice expressing insHEL, high avidity HEL-
reactive T cells are negatively selected during the CD4
 
 
 
8
 
 
 
double-positive and early single-positive stages. Thus, the
total number of double-positive cells is reduced 
 
 
 
50% and
the number of CD4 single-positive cells is dramatically de-
creased (Fig. 6, A and C). The CD4 single positives that
mature in these thymi carry greatly reduced clonotypic
TCR (Fig. 6 B and Fig. 7) and a smaller reduction in sur-
face CD3 and V
 
 
 
8 levels (Fig. 7), comparable to the CD4
cells found in the periphery of these mice (Fig. 3).
In double transgenic mice on the NOD
 
k
 
 background,
however, there is no reduction in the numbers of double-
positive cells and CD4 single-positive cells continue to be
formed in approximately the same frequency as in TCR
littermates (Fig. 6 A). These autoreactive single positive
thymocytes show no evidence of selection for low avidity
cells, as they continue to express high densities of clono-
typic TCR (Fig. 6 B) and high surface levels of CD3 and
V
 
 
 
8 (Fig. 7). As a result, whereas almost no high avidity
CD4 T cells recognizing islet HEL are formed in the thy-
mus of B10
 
k
 
 double transgenic mice, these cells continue to
be formed in NOD
 
k
 
 double transgenic thymi in numbers
that are only slightly reduced compared with animals lack-
ing the autoantigen (Fig. 6 D).
In theory, the presence of CD4
 
 
 
1G12
 
 
 
 cells in the thy-
mus of TCR/insHEL NOD
 
k
 
 mice could have resulted from
a peripheral tolerance defect, allowing recirculation of ma-
ture CD4
 
 
 
 cells back to the thymus after activation and ex-
pansion in the periphery. Three lines of evidence exclude
Figure 2. Failure to eliminate islet-reactive CD4 T cells in NODk
mice. (a) Spleen cells from 6–12-wk old nondiabetic female mice of the
indicated genotypes were stained with 1G12 anti-TCR clonotype and
antibody to CD4. The percentage of lymphocytes falling within the
quadrants is shown. (b) The same analysis performed on cells from pan-
creatic lymph nodes (pLN) and pancreatic islets of 6–12-wk old nondia-
betic TCR/insHEL mice. (c) Data collected as above compiled from
multiple animals of the indicated genotypes. 
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this possibility. First, negative selection is evident within the
double-positive population in B10
 
k
 
 but not in NOD
 
k
 
thymi. Second, high avidity autoreactive cells are present in
much higher numbers in NOD
 
k
 
 thymi of mice of various
ages, and they do not accumulate with age as would be ex-
pected for peripheral expansion (Fig. 8 A). Third, all of the
clonotype-high single positive thymocytes are CD24 (heat
stable antigen)
 
hi
 
, indicating that they are immature recently
formed T cells that have failed to be deleted, and not mature
cells that have homed back (Fig. 8 B).
 
T Cell Intrinsic Action of NOD Genes on Thymic Deletion to
Islet Antigen.
 
The failure to delete islet-HEL specific T
cells in the NOD
 
k
 
 double-transgenic mice could reflect
differences in the expression or presentation of insHEL to
T cells in the thymus, or differences in the way the imma-
ture T cells respond to self-antigen. To distinguish be-
tween these possibilities, we constructed radiation chime-
ras using mixtures of bone marrow from TCR-transgenic
mice of B10
 
k
 
 and NOD
 
k
 
 backgrounds to reconstitute le-
thally irradiated insHEL or nontransgenic recipients (Fig.
9 A). Leukocytes from the two donor strains could be dis-
tinguished by expression of different allelic forms of the
Ly5 (CD45) surface protein. F1 hybrid recipients were
used in most experiments, thus allowing any radioresistant
host T cells to be distinguished as Ly5
 
ab
 
 double-positive,
compared with the donor-derived T cell populations
which carry only one or other marker. In preliminary
studies using nontransgenic donor bone marrow, we
found that NOD
 
k
 
-derived T cells preferentially expand
within the CD4
 
 
 
8
 
 
 
 double-positive population of mixed
chimeras (Fig. 9 B). The preferential expansion of
NODk-derived cells could be offset by reconstituting
with bone marrow mixtures containing a 4:1 ratio of
Figure 3. Failure to downregulate
TCR expression in splenocytes of
NODk animals. (a) Spleen cells from
nondiabetic female mice of various
genotypes were stained with anti-
bodies to CD4, CD3, V 8, and
1G12 clonotype. Histograms show
profiles of CD4-positive cells from
mice of the indicated genotypes. (b)
V 3 expression on CD4 V 8 
spleen cells from B10k mice of the
indicated genotypes. (c) Staining for
an endogenous TCR-  chain, V 2,
on CD4  spleen cells. The per-
centage of CD4  cells that are
V 2  is indicated.
Figure 4. High TCR levels on lymphocytes in the islets of NODk
mice. Islets from nondiabetic female mice were purified and analyzed as
in Fig. 3 a.1181 Lesage et al.
B10k to NODk marrow (Fig. 9 C). Using 4:1 mixtures of
TCR transgenic marrow, chimeras were obtained that
formed comparably sized populations of single-positive T
cells and peripheral CD4  1G12  T cells in the absence
of insHEL (InsHEL ; Fig. 9, D and E).
When the same mixtures reconstituted negatively select-
ing thymuses of insHEL-transgenic recipients, by contrast,
B10k-derived T cells were selectively reduced in frequency
in the double-positive compartment and very few B10k
single-positive T cells or CD4 clonotype  T cells re-
mained. NODk-derived DP and single-positive T cells in
the same thymuses were not markedly deleted despite bear-
ing the same TCR and recognizing the same antigen/
MHC combination (Fig. 9 D). As a result, despite the chi-
meric mice being reconstituted with a fourfold excess of
B10k bone marrow, islet-reactive CD4 T cells in spleen
and pancreatic lymph node of the chimeric mice were al-
most entirely of NODk origin (Fig. 9 E). Thus, non-MHC
genes from NOD act cell autonomously within high avid-
ity autoreactive T cells to make them insensitive to thymic
negative selection.
Discussion
This study shows that self-reactive CD4 T cells bearing a
high affinity TCR for a dominant epitope of HEL fail to be
effectively censored during their development in the thy-
mus of NODk mice that are making HEL in pancreatic islet
  cells. The primary effect of the non-MHC genes from
NOD is within the high affinity autoreactive T cells, caus-
ing them to be insensitive to clonal deletion stimuli in the
thymus at the double-positive and CD4 CD24high single-
positive stages. In conjunction with this NOD defect in
thymic deletion, HEL-specific T cells specifically respond
to antigen in the pancreatic islets where T cell help be-
comes available, after a variable time-lag of weeks or
months, as evidenced by spontaneous development of ger-
minal centers and large amounts of HEL-binding IgG1 au-
toantibody, and gradual progression to diabetes. These re-
sults define an important primary defect in the thymic
selection and acquisition of T cell self-tolerance that is
likely to play an important part in the general autoimmune
susceptibility of NOD mice. The findings focus attention
on thymic selection mechanisms for organ specific toler-
Figure 5. T cell activation in the islets is specific to CD4 clonotype  NODk T cells. Lymphocytes from pancreatic lymph nodes and islets of two non-
diabetic TCR/insHEL female mice of B10k or NODk background were stained with CD4, 1G12 clonotype, and the activation marker CD69. The per-
centage of lymphocytes falling within the quadrants is indicated. Histograms show profiles of CD69 expression on clonotype-positive or clonotype-neg-
ative CD4 cells, overlaying cells from the islet and pancreatic lymph node of the same animal.1182 Failure of T Cell Deletion in Type I Diabetes
ance, and raise subsequent questions about how this defect
might arise and how it is connected to other genetic and
immunological defects described in mice and humans with
organ-specific autoimmune disease.
Negative selection of self-reactive thymocytes is strik-
ingly altered by non-MHC NOD genes acting within the
T cells. In the presence of insHEL self-antigen, HEL-spe-
cific T cells bearing B10 genes showed a marked deletion
Figure 6. Failure to delete islet-reactive T cells in the thymus of NODk animals. (a) Thymocytes from 6–12-wk old nondiabetic female mice of the in-
dicated genotypes were stained with 1G12 anti-TCR clonotype, and antibodies to CD4 and CD8. The percentage of CD4 CD8  and CD4 CD8 
thymocytes are shown. (b) The 1G12 profiles are shown for CD4 CD8  mature thymocytes. 1G12 staining cannot be detected on CD4 CD8  thy-
mocytes. (c) Absolute number of CD4 CD8  thymocytes was calculated for each group. From left to right, there were exactly 4, 6, 16, 3, 5, 13, and 10
mice, respectively. (d) Compilation of the number of CD4 1G12  thymocytes in each group.
Figure 7. Failure to downregulate TCR expression in CD4  thymocytes of NODk animals. (a) Thymocytes from nondiabetic female mice of various
genotypes were stained with antibodies to CD4, CD8, and 1G12 clonotype, together with either CD3 or V 8. All histograms show profiles of
CD4 CD8  cells, except for the graphs on the right which are gated on CD4 CD8  (DP) thymocytes.1183 Lesage et al.
in their numbers at the double-positive stage and relatively
few reached the single-positive stage (Figs. 6 and 7). By
contrast, T cells bearing the NOD genes showed little re-
duction in double-positive thymocytes and only a modest
decrease in single-positive thymocytes bearing the HEL-
specific TCR. Three lines of evidence establish that thymic
negative selection is the primary defect, and exclude the
possibility that the elevated numbers of CD4 single-posi-
tive T cells in the NODk thymus represent mature T cells
that have expanded in the periphery and then homed back
to the thymus. Foremost, the CD4 1G12  cells of NODk
InsHEL/TCR thymus are entirely immature CD24hi cells,
indicating they are recently differentiated rather than ma-
ture cells that have returned (Fig. 8). Second, deletion is
evident within the less mature CD4 8  cells in the B10k
animals but not in NODk (Fig. 6). Third, the numbers of
escaped CD4 1G12  thymocytes is highest in very young
mice an diminishes with age (Fig. 8), whereas the oppo-
site might be expected if the cells must first be expanded
in the periphery. The mixed bone marrow chimera ex-
periments exclude the possibility that differences in the
types of antigen-presenting cells or efficiency or types of
antigens presented to the T cells account for the failure to
censor the thymic and peripheral autoreactive T cell pop-
ulations, and demonstrate that NODk genes act within in-
dividual immature T cells to dramatically change the way
they respond to TCR engagement by negative selecting
autoantigen.
The thymic selection defects defined here are paralleled
by results from Kishimoto and Sprent (11) who have
shown that thymocytes from NOD mice are selectively re-
sistant to in vitro or in vivo negative selection induced by
anti-TCR and anti-CD28 antibodies or by bacterial su-
perantigens, when compared with B6-H-2nod congenic
controls. Since it is unclear how well anti-TCR or super-
antigen responses mirror the acquisition of tolerance to
self-antigens, our findings clearly establish that NOD genes
dramatically interfere with tolerance by negative selection
in vivo, as well as showing that these inherited defects act
cell autonomously within individual autoreactive CD4 cells.
The chief difference between the two analyses is the
finding by Kishimoto and Sprent that NOD thymocyte
apoptosis defects are only detectable in the DP-SP transi-
tional cell population in vitro, with normal apoptosis of
double-positive thymocytes. By contrast, NOD genes pre-
vented islet antigen induced deletion in DP and SP popula-
tions in vivo. This may reflect differences in the strength
and quality of signals provided by plate-bound antibodies
compared with antigen-presenting cells bearing trace
amounts of self-antigen. Of potentially greater significance,
however, is the finding here that peripheral autoreactive T
cells with the NOD genes fail to exhibit the modulation of
Figure 8. Increased CD4 1G12  thymocytes in
NODk insHEL/TCR mice is not due to mature T cell
recirculation to the thymus. (a) Absolute number of
CD4 1G12  mature thymocytes in insHEL/TCR
double transgenic on B10k, NODk, and F1 background
plotted versus age. (b) Thymocytes from insHEL/TCR
double transgenic mice were stained with 1G12, CD4,
CD8, and CD24. CD24 profiles are shown for 1G12-
positive or -negative CD4 CD8  mature thymocytes.1184 Failure of T Cell Deletion in Type I Diabetes
surface TCR density that is maintained by B10 T cells (Fig.
3). This result is at odds with the conclusion that NOD
genes selectively altered in vitro responses of thymocytes
but not of mature peripheral T cells (11) and indicates that
the inherited NOD T cell defect in sensitivity to autoanti-
gen may carry through to alter peripheral T cell regulation
as well. In this regard, non-MHC NOD genes have been
shown to render thymocytes, peripheral T cells and B cells
resistant to dexamethasone or cyclophosphamide-induced
apoptosis (12, 52, 53).
Biochemical differences in TCR signaling in thy-
mocytes from NOD mice have been previously shown by
Delovitch and colleagues (10). In particular they showed
that, compared with BALB/c thymocytes, the TCR on
NOD thymocytes is less efficient at activating the ZAP70/
ras/ERK pathway, which is known to be important for in-
ducing T cell-positive and -negative selection. It will be
important in future work to investigate whether inefficient
activation of this pathway explains the selection defects
identified here, and whether these signaling differences re-
flect inherited differences in components of the TCR
pathway itself or in modulating factors such as costimula-
tory or inhibitory receptors. The latter are interesting can-
didates since the genes for CD28 and CTLA-4 lie in chro-
mosomal regions of inherited diabetes susceptibility in
NOD (12, 54).
CD28 signaling is a potent enhancer of negative selec-
tion in double-positive thymocytes, and complete defi-
ciency of CD28 or its B7.1 ligand greatly accelerates the
onset of diabetes in NOD mice while deficiency of the B7.2
ligand triggers autoimmune neuritis (9, 25). The CTLA-4
receptor for B7 ligands also modulates TCR signaling ap-
Figure 9. Failure to delete islet-
reactive cells in NODk is T cell in-
trinsic. (a) Design of bone marrow
chimera experiment. (b) Nontrans-
genic Ly5ab recipients were reconsti-
tuted with a 1:1 mixture of bone
marrow from B10k and NODk non-
transgenic mice. The thymocytes
were stained with CD4, CD8, Ly5a
and Ly5b. Percentage of each thy-
mocyte subsets is shown for two
mice. (c) Percentage is as in b, ex-
cept that the ratio of B10k/NODk
bone marrow cells is 4:1. (d) InsHEL-
positive or -negative recipients were
reconstituted with a 4:1 ratio of
B10k/NODk marrow. Percentage of
thymocyte subsets is shown from
analysis of four nontransgenic and
eight insHEL-transgenic recipients.
(e) Percentage of peripheral lympho-
cytes bearing CD4 and the HEL-
reactive TCR from each donor ge-
notype from the mice in days.1185 Lesage et al.
parently acting at the level of TCR phosphorylation up-
stream of ZAP70 (55). In future experiments it will be im-
portant to map the inheritance of the thymic deletion
defect by intercrosses and use of congenic strains carrying
individual resistance loci.
It is interesting to consider that the intrinsic differences
in NOD thymocyte response to TCR signals may also ac-
count for reduced activity of regulatory cells (3, 6), NKT
cells (7, 8), and CD4 CD25  regulatory T cells (9) in this
strain. NKT cells are selected from double-positive thy-
mocytes to carry a particular TCR in response to an un-
known self-antigen presented by CD1 (56). Similarly,
anergic CD4 CD25  regulatory T cells are selected by
self-antigen during the double-positive to single-positive
transition (43), at the same stage that negative selection oc-
curs. The intrinsic defects in thymocyte response to self-
antigen observed here might therefore also diminish the se-
lection of NKT and CD4 CD25  cells. Thus, a single
primary defect in thymocyte selection could conceivably
create two separate secondary abnormalities contributing to
autoimmune susceptibility: increased numbers of high
avidity T cells recognizing organ-specific self-antigens and
decreased numbers of NKT cells or anergic CD4 25  cells
capable of regulating the autoreactive population.
The thymic selection defects described here could ac-
count for the observed increase in T cells capable of pro-
liferating to self antigens in NOD mice (13, 14) by allow-
ing more autoreactive T cells to leave the thymus.
Because the actual frequency of high avidity autoreactive
T cells is not measured by proliferation assays, it is never-
theless also possible that enhanced proliferation in these
assays reflects the deficiencies of NKT cells or CD4 25 
regulatory cells discussed above. In the Ridway and
Kanagawa studies, inefficient negative selection of thymic
or peripheral T cells was proposed but via a different
mechanism, namely reduced presentation of self-antigens
by the NOD I-Ag7 molecule. The defect in negative se-
lection defined here is clearly established to reside in the
responding T cells and not in the antigen-presenting cells,
but it is interesting to consider that the two heritable def-
icits may be additive or multiplicative: an MHC-linked
deficit in presentation of islet autoantigens by I-Ag7 may
compound the non-MHC linked deficit in TCR-induced
deletion in response to those antigens.
The insensitivity of NOD T cells to autoantigen may
apply both during thymic development and after emigra-
tion to the periphery (see above). If this can be confirmed,
the intrinsic T cell insensitivity caused by non-MHC
NOD genes may also diminish peripheral deletion of CD8
T cells that recognize organ specific autoantigens (16, 57).
Interestingly, Verdegauer found that diabetes resistance
genes from NOR caused fewer CD8 T cells with an islet-
reactive TCR to accumulate in the periphery (15). It is
unclear if the two results are related, however, since Ver-
daguer et al. found no evidence for thymic deletion in the
resistant background, homozygosity for resistance genes
was required, and the reduced number of islet reactive
cells may have been secondary to absence of helper cells
promoting expansion or to diminished presentation of the
islet autoantigen.
Is the failure to delete HEL-reactive T cells in the thy-
mus the sole cause of progression to diabetes in the NODk
double-transgenic mice? It is a straightforward extrapola-
tion to connect the increased number of high avidity HEL-
reactive T cells in the peripheral lymphoid tissues and pan-
creas to the formation of high titred IgG1 against HEL and
pancreatic germinal centers in these mice, since both of
these processes depend on cognate T cell help and no au-
toantibody is made in insHEL animals without the HEL-
specific TCR transgene. It is also a reasonable extrapolation
to assume that   cell destruction also results from the in-
creased numbers of HEL-reactive CD4 cells, since diabetes
in the NODk female mice requires both the TCR and
insHEL genes. Nontolerant T cells from 3A9 TCR trans-
genic are capable of rapid   cell destruction, because they
induce diabetes within 14 d after adoptive transfer into
unirradiated B10k insHEL recipients provided the recipi-
ents are immunized with HEL in adjuvant (unpublished
data). Nevertheless, it is striking that diabetes and anti-HEL
IgG antibody production in NODk double transgenic mice
occurs stochastically between 3 and 6 mo of age, despite all
of the mice having increased numbers of HEL-reactive T
cells and extensive insulitis at 6–8 wk old. Breakage of tol-
erance to HEL may take a variable period of time simply
because the high avidity HEL-reactive T cells must first or-
ganize the insulitis into supportive structures like germinal
centers, or it may require a separate deficit such as the reg-
ulatory abnormalities discussed above or an unknown ex-
ogenous insult.
It is interesting that progression to diabetes occurs by an
apparently distinct genetic and cellular mechanism in a sub-
set of B10k double transgenic mice (Fig. 1). In these ani-
mals, diabetes develops only at an 8–12 wk age window
and is not accompanied by any IgG1 secretion to insHEL,
and this form of diabetes is fully suppressed by a single set
of NODk chromosomes in F1 hybrids. The early onset dis-
ease linked to B10 genes has parallels to the early onset dia-
betes that occurs in BDC2.5 TCR transgenic mice on the
C57BL/6.H-2NOD strain background (35). A region on
chromosomes 7 from the related B6 or B10 strains has been
shown to contain a diabetes susceptibility genes, but it is
not yet known what gene or defect may be involved (35,
58, 59).
Despite the conceptually attractive idea that peripherally
induced mechanisms are critical for acquiring self-tolerance
to organ-specific antigens, the primary defect in thymic
negative selection found here indicates that thymic selec-
tion may play a more critical role than has been thought.
Indeed a growing body of evidence implicates thymic se-
lection as a critical step for organ-specific tolerance. In
quail/chicken chimeras, tolerance to a transplanted quail
wing bud is only acquired if some of the T cells develop in
a quail thymus (60, 61). Neonatal thymectomy in rodents
has long been known to lead to organ-specific autoimmune
diseases, notably autoimmune gastritis and oophoritis. Thy-
mic-derived T cells, notably a CD4 25  subset, have been1186 Failure of T Cell Deletion in Type I Diabetes
shown to be capable of suppressing autoimmune and im-
munopathologic reactions in thymectomized or T cell lym-
phopenic recipients (43–46). Deficiency of CD4 25  cells
and autoimmune disease in mice without IL-2 or IL-2R
may reflect a primarily thymic function of IL-2 in toler-
ance, because the IL-2Rb deficiency disorder is corrected
when expression of this receptor is limited to developing
thymocytes (62). A growing list of organ-specific genes has
been shown to be expressed in the thymus, especially in
thymic medullary epithelial cells (36, 37), and inheritance
of an insulin gene allele that causes lower thymic expres-
sion is associated with diabetes susceptibility in humans (63,
64). Finally, multiple organ-specific autoimmune diseases
develop in people with the inherited Mendelian disorder,
Autoimmune Polyendocrinopathy, resulting from loss of a
putative transcription factor primarily expressed in subsets
of thymic epithelial or dendritic cells (65–67).
Our results have implications for diabetes prevention and
therapy efforts. If similar defects in thymocyte or peripheral
T cell responses to self-antigens contribute to human type 1
diabetes, then agents that further lessen TCR signaling such
as cyclosporin or CD28/B7 blockade may be contraindi-
cated. These maneuvers may exaggerate the failure to cen-
sor self-reactive T cells and lead to worsening of disease or
development of other autoimmune diseases, as occurs
when NOD mice are made deficient for B7 or CD28 mol-
ecules (9, 25). Agents that nonspecifically augment costim-
ulation, stimulate negative selection selectively, or that
stimulate formation of regulatory T cells may be better at
correcting the primary defect in individuals with organ-
specific autoimmunity.
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